Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) gapped down before the market opened on Wednesday . The stock had previously closed at $0.29, but opened at $0.28. Synergy Pharmaceuticals shares last traded at $0.28, with a volume of 1376034 shares changing hands.
Several equities analysts have recently issued reports on the stock. BTIG Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. Canaccord Genuity cut shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. Synergy Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $5.33.
The company has a market capitalization of $70.24 million, a PE ratio of -0.27 and a beta of 4.94.
COPYRIGHT VIOLATION NOTICE: “Synergy Pharmaceuticals (SGYP) Shares Gap Down to $0.28” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.com-unik.info/2019/02/13/synergy-pharmaceuticals-sgyp-shares-gap-down-to-0-28.html.
About Synergy Pharmaceuticals (NASDAQ:SGYP)
Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.
Read More: What are the benefits of a balanced fund?
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.